Greatest effect of HPV vaccination from school-based programmes

The Lancet Infectious Diseases

Volumn 15, Issue 5, 2015, Pages 497-498

  Regan, David G ^a   Hocking, Jane S ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; CROSS PROTECTION; DEVELOPED COUNTRY; DISEASE SURVEILLANCE; EDUCATIONAL STATUS; HERD IMMUNITY; HUMAN; LOWEST INCOME GROUP; NOTE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL; SCHOOL HEALTH SERVICE; TREATMENT OUTCOME; VACCINATION; CONDYLOMATA ACUMINATA; FEMALE; IMMUNOLOGY; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

CONDYLOMATA ACUMINATA; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84928210882     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70078-2     Document Type: Note

References (13)

1. Countries using HPV vaccine WHO, (accessed Feb 2, 2015). http://www.who.int/immunization/diseases/hpv/decision_implementation/en/.
2. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
3. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
4. Bonanni P, Boccalini S, Bechini A Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009, 27(suppl 1):A46-A53.
5. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
6. Stanley M Prophylactic human papillomavirus vaccines: will they do their job?. J Intern Med 2010, 267:251-259.
7. Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis. Lancet Infect Dis 2015, published online March 3. http://dx.doi.org/10.1016/S1473-3099(14)71073-4.
8. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012, 30:5496-5499.
9. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015, 32:10-30.
10. Fisher H, Audrey S, Mytton JA, Hickman M, Trotter C Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. J Public Health 2014, 36:36-45.
11. Vandelaer J, Olaniran M Using a school-based approach to deliver immunization-global update. Vaccine 2015, 33:719-725.
12. Watson M, Lynch J, D'Onise K, Brotherton J Barriers to better three-dose coverage with HPV vaccination in school-based programs. Aust N Z J Public Health 2014, 38:91-92.
13. Korostil IA, Ali H, Guy RJ, Donovan B, Law MG, Regan DG Near elimination of genital warts in Australia predicted with extension of HPV vaccination to males. Sex Transm Dis 2013, 40:833-835.